Adial Pharmaceuticals, Inc. (ADIL) |
| 2.53 0 (0%) 02-27 16:00 |
| Open: | 2.59 |
| High: | 2.6256 |
| Low: | 2.47 |
| Volume: | 53,197 |
| Market Cap: | 2(M) |
| PE Ratio: | -0.16 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 6.00 |
| Resistance 1: | 4.58 |
| Pivot price: | 2.70 |
| Support 1: | 2.27 |
| Support 2: | 1.89 |
| 52w High: | 30.25 |
| 52w Low: | 2.27 |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Financials
| EPS | -15.000 |
| Book Value | 4.720 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -79.4 |
| Return on Equity (ttm) | -155.0 |
Company news
Tue, 24 Feb 2026
ARMISTICE CAPITAL, LLC Acquires Shares in Adial Pharmaceuticals Inc - GuruFocus
Tue, 24 Feb 2026
Adial Regains Nasdaq Compliance as AD04 Advances, Engages in Partnering Talks - TradingView
Tue, 24 Feb 2026
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - GlobeNewswire
Tue, 24 Feb 2026
Adial cleared by Nasdaq after 10 days with shares at $1 or more - Stock Titan
Mon, 23 Feb 2026
Adial Pharmaceuticals (ADIL) Sees Potential in FDA's New Approva - GuruFocus
Mon, 23 Feb 2026
New FDA trial policy could speed addiction drug for heavy drinkers - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
